C2N Diagnostics Lowers Age Limit for Alzheimer’s Blood Test to 50
C2N Diagnostics has expanded the intended use of its PrecivityAD2 Alzheimer's disease blood test to include patients 50 years and older, lowering the previous age limit from 60 years.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Are AI-Powered Neurodiagnostic Solutions the New Frontier in Alzheimer’s Prevention?
AI-enhanced EEG technology offers a promising, accessible way to detect early signs of Alzheimer’s disease—years before symptoms appear.
Dementias & Alzheimer’s
Latest
Blood Test Provides Accurate Results for Alzheimer’s Detection
A large international study found that a simpler blood test method using plasma P-tau217 can accurately detect Alzheimer’s disease.
Blood Test May Be Means for Early Detection of Dementia
A blood test originally developed for Alzheimer’s can help predict dementia in patients with iRBD years before symptoms appear.
Read More
P-tau not as Disease-Specific for Alzheimer’s as Previously Thought
The detection of p-tau proteins in the blood for early Alzheimer’s disease (AD) diagnosis is less specific than previously believed.
Read More
Study Aims to Identify New Auditory Biomarkers
The SAPHIR study aims to develop auditory biomarkers for early detection and improved disease management related to cognitive decline.
Read More
Biomarker Test Can Detect Alzheimer’s Earlier
A biomarker test can detect early-stage tau protein clumping associated with Alzheimer’s disease up to a decade before tau tangles appear.
Read More
Unifying Model of Alzheimer’s Disease Proposed
Scientists have proposed a unifying explanation for Alzheimer’s disease, linking widespread gene disruption to chronic stress granules.
Read More
Mouth Bacteria May Give Window into Future Brain Function
Research suggests that mouth bacteria may influence memory and cognitive function, some promoting brain health while others risk Alzheimer’s.
Read More
Neurocode Study Compares Alzheimer’s Assays
Neurocode USA Inc. published a study showing that its ALZpath pTau217 assay outperforms the Fujirebio assay in detecting Alzheimer’s disease.
Read More
Alzheimer’s Disease Blood Biomarker Test Improves Clinical Decision-Making
The use of the PrecivityAD2 blood biomarker test significantly improved clinicians’ confidence in diagnosing Alzheimer’s disease.
Read More
FDA Grants Breakthrough Device Designation for Beckman Coulter Alzheimer’s Blood Test
The FDA granted Breakthrough Device Designation to Beckman Coulter’s Access p-Tau217/β-Amyloid 1-42 plasma ratio blood test.
Read More
New Biomarker Tests Enable Early Diagnosis of Synucleinopathies
A new expert-led paper highlights the potential of biomarker testing to improve early diagnosis and treatment of synucleinopathies.
Read More
New Guidelines Developed to Diagnose Common Memory Disorder Mistaken for Alzheimer’s
New guidelines for limbic-predominant age-related TDP-43 encephalopathy aim to differentiate the memory-loss syndrome from Alzheimer’s.
Read More
New Blood Biomarkers Could Transform Alzheimer’s Diagnosis
Declining blood levels of acetyl-L-carnitine and free carnitine are closely linked to Alzheimer’s severity, with sex-specific differences.
Read More
Breakthrough Device Designation Granted to pTau 217 Blood Test for Alzheimer’s Detection
Spear Bio’s pTau 217 blood test, a less-invasive solution for early Alzheimer’s diagnosis, received an FDA Breakthrough Device Designation.
Read More
Structure of Huntington’s Disease Protein Clumps Identified
Researchers have visualized the atomic-level structure of protein clumps linked to Huntington’s disease, paving the way for diagnostic tools.
Read More
Alpha-Synuclein: Adding Precision to Neurodegenerative Testing
This episode of Clinical Lab Chat covers the how and why of making precise clinical diagnosis of neurodegenerative diseases.
Read More